PARNAXLAB
Parnax Lab financials
- Market cap
- ₹144 Cr
- Sector
- Healthcare
Quarterly results
Q1 FY27: revenue up 6.4%, net profit down 86.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48 | 40 | 49 | 53 | 63 +29% | 63 +56% | 70 +42% | 57 +6% |
| EBITDA | 7 | 4 | 7 | 7 | 8 +12% | 7 +60% | 5 −26% | 4 −42% |
| Net profit | 3 | 1 | 3 | 3 | 4 +6% | 3 +124% | 2 −25% | 0 −87% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −10.2% 1Y
1Y: ₹141.45 on 10 Sept 2025 → ₹127. High ₹165 (27 Apr 2026), low ₹106.6 (21 Jan 2026).
Financials, as filed
Revenue grew 14.8% a year over 2 years, FY24 to FY26. Operating margin narrowed to 11.0%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹189 Cr | ₹188 Cr | ₹249 Cr |
| Operating profit | ₹24 Cr | ₹27 Cr | ₹27 Cr |
| Operating margin | 12.5% | 14.3% | 11.0% |
| Interest | ₹5 Cr | ₹5 Cr | ₹6 Cr |
| Depreciation | ₹7 Cr | ₹7 Cr | ₹8 Cr |
| Net profit | ₹10 Cr | ₹12 Cr | ₹12 Cr |
| Net margin | 5.1% | 6.2% | 4.7% |
| Cash from operations | ₹16 Cr | ₹32 Cr | ₹8 Cr |
| Free cash flow | ₹-16 Cr | ₹16 Cr | ₹-9 Cr |
| ROCE | 13.0% | 14.0% | 14.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹8 Cr | ₹10 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr |
| Reserves | ₹24 Cr | ₹38 Cr | ₹51 Cr | ₹60 Cr | ₹78 Cr | ₹84 Cr |
| Borrowings | ₹59 Cr | ₹69 Cr | ₹55 Cr | ₹81 Cr | ₹69 Cr | ₹83 Cr |
| Other liabilities | ₹15 Cr | ₹36 Cr | ₹28 Cr | ₹38 Cr | ₹50 Cr | ₹50 Cr |
| Total liabilities | ₹106 Cr | ₹153 Cr | ₹145 Cr | ₹190 Cr | ₹208 Cr | ₹228 Cr |
| Fixed assets | ₹60 Cr | ₹72 Cr | ₹77 Cr | ₹89 Cr | ₹113 Cr | ₹115 Cr |
| Capital work in progress | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹21 Cr | ₹14 Cr | ₹11 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹41 Cr | ₹78 Cr | ₹66 Cr | ₹80 Cr | ₹82 Cr | ₹101 Cr |
| Total assets | ₹106 Cr | ₹153 Cr | ₹145 Cr | ₹190 Cr | ₹208 Cr | ₹228 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 17% to 3,572.
- Promoters
- 72.3%
- Public
- 27.7%
Since Jun 2025
- Public +0.01 pp
- Promoters 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 72.3%, Public 27.7%.Dec '23: Promoters 72.3%, Public 27.7%.Mar '24: Promoters 72.3%, Public 27.7%.Jun '24: Promoters 72.3%, Public 27.7%.Sep '24: Promoters 72.3%, Public 27.7%.Dec '24: Promoters 72.3%, Public 27.7%.Mar '25: Promoters 72.3%, Public 27.7%.Jun '25: Promoters 72.3%, Public 27.7%.Sep '25: Promoters 72.3%, Public 27.7%.Dec '25: Promoters 72.3%, Public 27.7%.Mar '26: Promoters 72.3%, Public 27.7%.Jun '26: Promoters 72.3%, Public 27.7%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Tradelink Exim India Private Limited newly disclosed 1.35% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Parnax Lab Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Binoy Baiju Shah | 11.92% | unchanged |
| Ila B Shah | 11.86% | unchanged |
| Baiju Mahasukhlal Shah | 11.57% | unchanged |
| Prakash Mahasukhlal Shah | 10.46% | unchanged |
| Mihir Prakash Shah | 9.94% | unchanged |
| Pragna Prakash Shah | 9.28% | unchanged |
| Ami Mihir Shah | 7.26% | unchanged |
| Suman Gupta | 1.62% | unchanged |
| Tradelink Exim India Private Limited | 1.35% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
ExpensiveTo justify its price of ₹127, this stock must grow earnings at 12% every year for 7 years. Our analysis caps realistic growth at ~3%. At that growth it is worth ₹80 — downside of 37%.
- Growth the price implies
- 12.0% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 3.3% a year
- net profit, FY24–FY26 · EPS 3.3%
- The gap
- 0.1 pp
- -37% downside if it only repeats history
Learn to analyse Parnax Lab Limited
Guides on how to read this kind of business and the numbers that matter.